Translationally Controlled Tumor Protein Enhances Angiogenesis in Ovarian Tumors by Activating Vascular Endothelial

Seung Bae Rho1, Boh-Ram Kim2, Seung-Hoon Lee3

  • 1Division of Cancer Biology, Research Institute, National Cancer Center, Goyang 10408, Republic of Korea.

Biomolecules & Therapeutics
|December 12, 2024
PubMed

Insights

Translationally controlled tumor protein (TCTP) promotes tumor angiogenesis by interacting with VEGF receptor 2. Inhibiting TCTP reduces tumor cell proliferation and angiogenesis via key signaling pathways.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Cell Biology

Background:

  • Translationally controlled tumor protein (TCTP) is a key regulator in cellular processes.
  • The precise mechanism of TCTP's role in tumor angiogenesis remains largely unknown.

Purpose of the Study:

  • To elucidate the molecular mechanisms by which TCTP stimulates angiogenesis.
  • To investigate TCTP's interaction with VEGF receptor 2 (VEGFR-2) and downstream signaling pathways.

Main Methods:

  • Utilized recombinant TCTP and short interfering TCTP (siTCTP) in cellular assays.
  • Assessed endothelial cell migration, proliferation, and capillary-like structure formation in vitro.
  • Examined the expression and phosphorylation of key proteins including VEGFR-2, VEGF, HIF-1α, PI3K, Akt, and mTOR.

Main Results:

  • Recombinant TCTP enhanced VEGF-induced endothelial cell functions via VEGFR-2 interaction.
  • siTCTP significantly decreased ovarian tumor cell proliferation and angiogenesis.
  • siTCTP inhibited VEGFR-2 tyrosine phosphorylation and downstream PI3K/Akt/mTOR signaling, reducing VEGF and HIF-1α expression.

Conclusions:

  • TCTP promotes tumor cell proliferation and angiogenesis through the VEGFR-2/PI3K/mTOR signaling pathway.
  • These findings offer novel insights into TCTP's function in tumor angiogenesis and potential therapeutic targets.

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.7K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K